title: Cryptogenic Organizing Pneumonia: IL-1β, IL-6, IL-8, and TGF- β1 Serum Concentrations and Response to Clarithromycin Treatment.
abstract: Cryptogenic organizing pneumonia (COP) is a distinct clinicopathological entity with unknown etiology. Inflammatory cytokines play a role in the development of the disease. The present study was performed to assess the correlation between concentrations of IL-1β, IL-6, IL-8, and TGF-β1 in the serum with response to clarithromycin (CAM) treatment in patients with COP. A total of 39 patients with COP were enrolled in to this study. An oral dose of 500 mg CAM was administered to all of the patients twice daily for 3 months. A complete response was noticed in 31 (80 %) of patients, and 8 (20 %) patients failed to respond to treatment. The concentration of cytokines were assessed by ELISAs before and after treatment. CAM treatment was associated with decreases in serum IL-6 (3.8 pg/mL [IQR 0.9-11.8] vs. 1.1 pg/mL [IQR 0.2-3.1]; p = 0.004), IL-8 (13.6 pg/mL [IQR 9.8-17.5] vs. 8.1 pg/mL [IQR 6.2-13.2]; p = 0.004), and TGF-β1 (37.1 ng/mL [IQR 31.7-46.2] vs. 25.7 ng/mL [IQR 22-41.7];p = 0.0001), which was particularly notable in the responders. We conclude that IL-6, IL-8, and TGF-β1 may play a role in the pathogenesis of COP, as their decreased concentrations were associated with a positive response to CAM treatment.
authors.affiliation: Third Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 26 Płocka St, 01-138, Warsaw, Poland. e.radzikowska@wp.pl.
authors.forename: E
authors.initials: E
authors.lastname: Radzikowska
authors.affiliation: Department of Genetics and Clinical Immunology, National Tuberculosis and Lung Diseases Research Institute, 26 Płocka St, 01-138, Warsaw, Poland.
authors.forename: A
authors.initials: A
authors.lastname: Roży
authors.affiliation: Department of Genetics and Clinical Immunology, National Tuberculosis and Lung Diseases Research Institute, 26 Płocka St, 01-138, Warsaw, Poland.
authors.forename: P
authors.initials: P
authors.lastname: Jaguś
authors.affiliation: Third Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 26 Płocka St, 01-138, Warsaw, Poland.
authors.forename: E
authors.initials: E
authors.lastname: Wiatr
authors.affiliation: Third Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 26 Płocka St, 01-138, Warsaw, Poland.
authors.forename: D
authors.initials: D
authors.lastname: Gawryluk
authors.affiliation: Department of Genetics and Clinical Immunology, National Tuberculosis and Lung Diseases Research Institute, 26 Płocka St, 01-138, Warsaw, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Chorostowska-Wynimko
authors.affiliation: Third Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 26 Płocka St, 01-138, Warsaw, Poland.
authors.forename: K
authors.initials: K
authors.lastname: Roszkowski-Śliż
mesh_terms: D000368:Aged; D015415:Biomarkers / Q000097:blood*; D017291:Clarithromycin / Q000627:therapeutic use*; D018549:Cryptogenic Organizing Pneumonia / Q000097:blood* / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053583:Interleukin-1beta / Q000097:blood*; D015850:Interleukin-6 / Q000097:blood*; D016209:Interleukin-8 / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011500:Protein Synthesis Inhibitors / Q000627:therapeutic use; D053773:Transforming Growth Factor beta1 / Q000097:blood*
chemical_list: D015415:Biomarkers; C508606:CXCL8 protein, human; C508600:IL6 protein, human; D053583:Interleukin-1beta; D015850:Interleukin-6; D016209:Interleukin-8; D011500:Protein Synthesis Inhibitors; D053773:Transforming Growth Factor beta1; D017291:Clarithromycin
keywords: Clarithromycin; Cryptogenic organizing pneumonia; Cytokines; Interleukins; Pneumonia; Transforming growth factor-β